Site Search
Displaying results 61 - 70 of 573
Resource | Publications,
This policy brief is for country-level programme managers, technical advisers and procurement bodies involved in the process of procuring, introducing and scaling up optimal antiretroviral therapy for infants and young children living with HIV in low and middle-income countries. With multiple new antiretroviral drug options and the availability of new evidence, antiretroviral therapy for children is a dynamic and rapidly evolving space. Although critical tools such as the antiretroviral drug optimal formulary are periodically updated to support product selection, programmes must stay informed and up to date on availability of currently used antiretroviral drug formulations for children and anticipated new products to ensure that all children have access to the best available treatment for HIV infection.
Resource | Publications,
This progress report reviews recent gains, new developments and remaining challenges as countries approach the 2020 targets of the Start Free Stay Free AIDS Free framework.
Resource | Publications,
The objective of this report is to assess the situational landscape during mid-May 2020 surrounding the value chain of the production and distribution of generic antiretroviral medicines in low- and-middle-income countries and to provide recommendations on mitigating the risks of potential disruptions.
Resource | Guidelines,
The operational handbook provides practical information and tools that complement the recommendations in the guidelines. The strategies described in the operational handbook are based on the latest WHO recommendations which were formulated by Guideline Development Groups using the GRADE approach. In many cases however, the recommendations in their current form lacked sufficient clinical and programmatic detail, which is important for implementation. This operational handbook complements the guidelines with practical advice based on best practices and knowledge from the fields such as pharmacokinetics, pharmacodynamics, microbiology, pharmacovigilance and clinical and programmatic management.
Resource | Guidelines,
The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and MDR/RR-TB, including longer regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. The guidelines are to be used primarily in national TB programmes, or their equivalents in Ministries of Health, and for other policy-makers and technical organizations working on TB and infectious diseases in public and private sectors and in the community.
Financing Prevention, Testing and Treatment of Hepatitis in the Context of Universal Health Coverage
Resource | Publications,
A side event was held at the 2019 conference for the replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria in October 2019 to consider the effective use of global health resources. The meeting underscored the potential public health impact of expanding viral hepatitis elimination programming through strategic integration, including integration with existing efforts to eliminate AIDS and TB.
Conclusions outlined in this report call for the integration of the viral hepatitis response within programmes funded by the Global Fund and other funding agencies under a broader logic of UHC, as well as the establishment of catalytic funding for setting up and implementing national hepatitis plans.
Resource | Guidelines,
Despite increases in access to antiretroviral therapy (ART), declines in AIDS-related deaths have plateaued in recent years. Even after starting ART, patients with severe immunosuppression have a high risk of death. Implementing a package of care for patients with advanced HIV disease is critical; however, identifying those in need has remained a challenge.
Resource | Publications,
The main purpose of this guidance is to provide recommendations for preventing COVID-19 cross infection among beneficiaries and staff involved in the implementation of food and nutrition assistance for PLHIV and TB clients, while ensuring the continuity of food and nutrition assistance to PLHIV and TB, introducing adaptations where appropriate. Implementation of these recommendations should be done in alignment with country-specific guidance from national government.
Resource | Publications,
Based on the available evidence and success stories such as those cited, more and more countries are scaling-up the implementation of appointment-spacing and MMD. This Standard Operation Procedure (SOP) is designed to help ART service providers in Cambodia implement appointment-spacing and MMD for eligible patients – that is, patients whose condition is determined to be stable – which will reduce the need for frequent visits and help to reduce providers’ workload.
Resource | Publications,
The rise in antimicrobial resistance (AMR) is one of the greatest threats to global health. If it is not urgently addressed, it may result in millions of deaths, an increase in new and hard-to-treat infections and increased health-care costs. As a result, combatting AMR, including the threat posed by drug-resistant HIV, is a major goal for the global community.
Prevention, monitoring and timely response to population levels of HIV drug resistance (HIVDR) is critical to achieving the WHO/UNAIDS 90–90–90 targets for 2020 that 90% of people living with HIV know their HIV status, 90% of those who know their HIV-positive status are accessing treatment and 90% of the people receiving treatment having suppressed viral loads.